HONG KONG, May 20, 2025/PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a volume-matched placebo, alongside four weekly doses of semaglutide (0.5 mg). This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.